UK Markets close in 3 hrs 49 mins
  • FTSE 100

    6,331.67
    -31.26 (-0.49%)
     
  • FTSE 250

    19,213.65
    -182.69 (-0.94%)
     
  • AIM

    1,038.55
    +0.52 (+0.05%)
     
  • GBP/EUR

    1.1177
    -0.0034 (-0.30%)
     
  • GBP/USD

    1.3329
    -0.0028 (-0.2079%)
     
  • BTC-GBP

    12,747.52
    -107.54 (-0.84%)
     
  • CMC Crypto 200

    332.32
    -38.20 (-10.31%)
     
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • CRUDE OIL

    45.38
    -0.33 (-0.72%)
     
  • GOLD FUTURES

    1,808.90
    -2.30 (-0.13%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,322.64
    +36.07 (+0.27%)
     
  • CAC 40

    5,594.66
    +27.87 (+0.50%)
     

NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

NuCana plc
·4-min read

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

Event: Piper Sandler 32nd Annual Healthcare Conference
Pre-Recorded Presentation Replay: November 23, 2020 – December 3, 2020

The presentation will be pre-recorded and available for replay starting Monday, November 23, 2020 at 10:00 AM ET under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com.

About NuCana plc

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

Forward-Looking Statements

This press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

Hugh S. Griffith
Chief Executive Officer
NuCana plc
Tel: +44 131 357 1111
info@nucana.com

Westwicke, an ICR Company
Chris Brinzey
Tel: +1 339-970-2843
chris.brinzey@westwicke.com

RooneyPartners
Marion Janic
Tel: +1 212-223-4017
mjanic@rooneyco.com